Abeona reports top-line Phase I/II data for ABO-102 in mucopolysaccharidosis IIIA

In October, Abeona Therapeutics Inc. (NASDAQ:ABEO) reported top-line data from the first cohort of 3 patients with mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo type A syndrome) in a Phase I/II trial

Read the full 308 word article

User Sign In